Skip to search formSkip to main contentSkip to account menu

GC33

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Anti-GPC3 Monoclonal Antibody GC33

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).
4100 Background: GC33 is a recombinant humanized monoclonal antibody against Glypican-3 (GPC3) which is highly expressed in HCC… 
2014
2014
Biomarker analysis of a randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous RO5137382/GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced…
e15090 Background: Glypican-3 (GPC3) is an oncofetal protein frequently expressed in HCC. GC33 is a humanized monoclonal antibody… 
2013
2013
A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC).
235 Background: Glypican-3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically expressed… 
2011
2011
A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC).
4085 Background: Glypican 3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically… 
2008
2008
Human Liver Cancer Glypican 3 Antibody as a Potential Antitumor Agent for − Anti
Human glypican 3 (GPC3) is preferentially expressed in the tumor tissues of liver cancer patients. In this study, we obtained a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)